|
US713485A
(en)
|
1902-05-15 |
1902-11-11 |
Joseph Neumeier |
Well-tube lifter.
|
|
WO1989007105A1
(fr)
|
1988-02-04 |
1989-08-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Derives de staurosporine
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
|
MX9707453A
(es)
|
1995-03-30 |
1997-12-31 |
Pfizer |
Derivados de quinazolina.
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
FR2741881B1
(fr)
|
1995-12-01 |
1999-07-30 |
Centre Nat Rech Scient |
Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
|
|
US5989591A
(en)
|
1997-03-14 |
1999-11-23 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
PL215901B1
(pl)
|
1999-04-15 |
2014-02-28 |
Bristol Myers Squibb Co |
Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
|
|
CA2376596C
(en)
|
1999-06-25 |
2009-10-06 |
Genentech, Inc. |
Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
|
CZ301689B6
(cs)
|
1999-11-05 |
2010-05-26 |
Astrazeneca Ab |
Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
CA2397593C
(en)
|
2000-01-18 |
2009-11-10 |
Aventis Pharmaceuticals Inc. |
Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
|
|
SI1255752T1
(sl)
|
2000-02-15 |
2007-12-31 |
Pharmacia & Upjohn Co Llc |
S pirolom substituirani zaviralci 2-indolinon protein kinaza
|
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
PE20011178A1
(es)
|
2000-04-07 |
2001-11-19 |
Takeda Chemical Industries Ltd |
Compuestos heterociclicos y su produccion
|
|
ES2639222T5
(es)
|
2000-10-06 |
2023-11-24 |
Kyowa Kirin Co Ltd |
Células que producen unas composiciones de anticuerpo
|
|
DE60137273D1
(de)
|
2000-10-20 |
2009-02-12 |
Eisai R&D Man Co Ltd |
Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
|
|
DE10063435A1
(de)
|
2000-12-20 |
2002-07-04 |
Boehringer Ingelheim Pharma |
Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1652847B1
(en)
|
2001-04-27 |
2008-05-28 |
Kirin Pharma Kabushiki Kaisha |
Quinoline and quinazoline derivatives for the treatment of tumors
|
|
ATE334671T1
(de)
|
2001-09-14 |
2006-08-15 |
Univ Arizona |
Wortmanninanaloge und verfahren zu deren verwendung
|
|
ES2269793T3
(es)
|
2001-10-30 |
2007-04-01 |
Novartis Ag |
Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
|
US7119200B2
(en)
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
UA82205C2
(en)
|
2002-09-30 |
2008-03-25 |
Байер Фармасьютикалз Корпорейшн |
Fused azole-pyrimidine derivatives
|
|
PT2213661E
(pt)
|
2003-09-26 |
2011-12-15 |
Exelixis Inc |
Moduladores de c-met e métodos de uso
|
|
DE10349423A1
(de)
|
2003-10-16 |
2005-06-16 |
Schering Ag |
Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
CA2550361C
(en)
|
2003-12-19 |
2014-04-29 |
Prabha Ibrahim |
Compounds and methods for development of ret modulators
|
|
CN1972688B
(zh)
|
2004-05-06 |
2012-06-27 |
沃尼尔·朗伯有限责任公司 |
4-苯胺基-喹唑啉-6-基-酰胺类化合物
|
|
ES2540987T3
(es)
|
2004-05-14 |
2015-07-15 |
Millennium Pharmaceuticals, Inc. |
Métodos para preparar inhibidores de la aurora cinasa
|
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
|
JP4982364B2
(ja)
|
2004-07-19 |
2012-07-25 |
オンコノバ セラピューティクス インコーポレイテッド |
（ｅ）−２，６−ジアルキルオキシスチリル４−置換ベンジルスルフォン非経口用投与用製剤
|
|
BR122020017756B1
(pt)
|
2004-08-26 |
2022-02-15 |
Pfizer Inc |
Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
|
|
MX2007004781A
(es)
|
2004-10-20 |
2007-05-11 |
Applied Research Systems |
Derivados de 3-arilamino piridina.
|
|
US8975248B2
(en)
*
|
2004-12-15 |
2015-03-10 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combinations of therapeutic agents for treating cancer
|
|
MX2008002114A
(es)
|
2005-07-21 |
2008-04-17 |
Ardea Biosciences Inc |
Inhibidores de n-(arilamino)-sulfonamida de mek.
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
NZ568325A
(en)
|
2005-11-16 |
2011-05-27 |
S Bio Pte Ltd |
Macrocyclic oxygen linked pyrimidine derivatives
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
SI2495016T1
(sl)
|
2005-12-23 |
2020-04-30 |
Ariad Pharmaceuticals, Inc. |
Biciklične heteroarilne spojine
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
CA2647632C
(en)
|
2006-03-27 |
2017-06-27 |
University Of Maryland Biotechnology Institute |
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
|
|
PE20080359A1
(es)
|
2006-04-19 |
2008-06-06 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
US8563596B2
(en)
|
2006-06-21 |
2013-10-22 |
Piramal Enterprises Limited |
Enantiomerically pure compounds for the treatment of proliferative disorders
|
|
UA95641C2
(xx)
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
ME02372B
(me)
|
2006-11-22 |
2016-06-20 |
Incyte Holdings Corp |
Imidazotriazini i imidazopiramidini kao inhibitori kinaze
|
|
WO2008070740A1
(en)
|
2006-12-07 |
2008-06-12 |
F.Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
SG178789A1
(en)
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
US8163923B2
(en)
|
2007-03-14 |
2012-04-24 |
Advenchen Laboratories, Llc |
Spiro substituted compounds as angiogenesis inhibitors
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PH12013501594A1
(en)
|
2007-07-20 |
2014-05-12 |
Nerviano Medical Sciences Srl |
Substituted indazole derivatives active as kinase inhibitors
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
PT2300013T
(pt)
|
2008-05-21 |
2017-10-31 |
Ariad Pharma Inc |
Derivados de fósforo como inibidores de cinases
|
|
AP2775A
(en)
|
2008-05-23 |
2013-09-30 |
Wyeth Llc |
Triazine compounds as P13 kinase and MTOR inhibitors
|
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
|
AR074481A1
(es)
|
2008-12-05 |
2011-01-19 |
Abbott Lab |
Derivados de tienopiridina como inhibidores de quinasa
|
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
EP3613729A1
(en)
|
2009-06-10 |
2020-02-26 |
Chugai Seiyaku Kabushiki Kaisha |
Tetracyclic compounds
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
CN102020639A
(zh)
|
2009-09-14 |
2011-04-20 |
上海恒瑞医药有限公司 |
6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
|
|
BR112012030711B1
(pt)
|
2010-05-31 |
2020-10-13 |
Ono Pharmaceutical Co. Ltd |
derivado de purinona
|
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
|
KR102051881B1
(ko)
|
2010-10-25 |
2019-12-04 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
BR112014001255B1
(pt)
|
2011-07-19 |
2019-07-02 |
Merck Sharp & Dohme B.V. |
Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
|
|
CN103702990B
(zh)
|
2011-07-27 |
2015-09-09 |
阿斯利康(瑞典)有限公司 |
2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
|
|
RU2629116C2
(ru)
|
2011-10-14 |
2017-08-24 |
Эррэй Биофарма Инк. |
Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
|
|
HUE045957T2
(hu)
|
2011-12-30 |
2020-01-28 |
Hanmi Pharm Ind Co Ltd |
Proteinkináz inhibitor hatású tieno[3,2-d]pirimidin származékok
|
|
CA2862925C
(en)
|
2012-02-10 |
2020-01-21 |
University Of Maryland, Baltimore |
Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
|
|
SI2834241T1
(sl)
|
2012-03-05 |
2021-06-30 |
Gilead Calistoga Llc |
Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
|
|
HUE034118T2
(en)
|
2012-03-06 |
2018-01-29 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
|
WO2014022975A1
(zh)
|
2012-08-07 |
2014-02-13 |
上海创诺医药集团有限公司 |
N-(4-(3-氨基-1h-吲唑-4-基)苯基)-n'-(2-氟-5-甲基苯基)脲及其中间体的制备方法
|
|
DK2907824T3
(en)
*
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
KR20140096571A
(ko)
|
2013-01-28 |
2014-08-06 |
한미약품 주식회사 |
1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
|
|
AU2014214846A1
(en)
|
2013-02-08 |
2015-07-23 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
JP6363120B2
(ja)
|
2013-03-13 |
2018-07-25 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ベンゾオキサゼピン化合物の作製方法
|
|
US9067914B1
(en)
|
2013-12-10 |
2015-06-30 |
Genzyme Corporation |
Tropomyosin-related kinase (TRK) inhibitors
|
|
LT3424955T
(lt)
*
|
2013-12-25 |
2025-06-25 |
Daiichi Sankyo Company, Limited |
Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
|
|
SI3466976T1
(sl)
*
|
2014-01-31 |
2021-12-31 |
Daiichi Sankyo Company, Limited |
Anti-her2 konjugat protitelesa-zdravila
|
|
JP2017114763A
(ja)
|
2014-03-26 |
2017-06-29 |
第一三共株式会社 |
抗ｃｄ９８抗体−薬物コンジュゲート
|
|
JP6612738B2
(ja)
|
2014-04-10 |
2019-11-27 |
第一三共株式会社 |
抗ｈｅｒ２抗体−薬物コンジュゲート
|
|
KR102399277B1
(ko)
*
|
2014-04-10 |
2022-05-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
TWI704151B
(zh)
|
2014-12-22 |
2020-09-11 |
美商美國禮來大藥廠 |
Ｅｒｋ抑制劑
|
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
|
EP4180455A1
(en)
|
2015-06-29 |
2023-05-17 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
EP4212536B1
(en)
|
2015-07-02 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Benzoxazepin oxazolidinone compounds and methods of use
|
|
CN109803968A
(zh)
|
2016-08-15 |
2019-05-24 |
辉瑞公司 |
吡啶并嘧啶酮cdk2/4/6抑制剂
|
|
KR20240074000A
(ko)
*
|
2017-02-28 |
2024-05-27 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
|
|
TW202532102A
(zh)
*
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
ES3057444T3
(en)
|
2017-08-31 |
2026-03-02 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|